Acadian Asset Management LLC Increases Stake in BioCryst Pharmaceuticals, Inc. $BCRX

Acadian Asset Management LLC increased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 244.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 670,361 shares of the biotechnology company’s stock after buying an additional 475,564 shares during the period. Acadian Asset Management LLC owned about 0.32% of BioCryst Pharmaceuticals worth $5,023,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in BCRX. Headlands Technologies LLC bought a new stake in BioCryst Pharmaceuticals during the first quarter valued at about $32,000. GF Fund Management CO. LTD. bought a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at about $33,000. GAMMA Investing LLC boosted its position in BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 5,449 shares in the last quarter. New Age Alpha Advisors LLC bought a new stake in BioCryst Pharmaceuticals during the first quarter valued at about $62,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in BioCryst Pharmaceuticals during the first quarter valued at about $79,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Down 2.0%

Shares of NASDAQ:BCRX opened at $7.91 on Friday. BioCryst Pharmaceuticals, Inc. has a 12-month low of $6.01 and a 12-month high of $11.31. The company has a market capitalization of $1.66 billion, a PE ratio of -43.94, a PEG ratio of 1.83 and a beta of 1.13. The business has a 50 day moving average of $8.43 and a two-hundred day moving average of $8.73.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.12. The business had revenue of $163.35 million for the quarter, compared to analyst estimates of $149.59 million. During the same period in the previous year, the company earned ($0.06) earnings per share. The company’s quarterly revenue was up 49.5% compared to the same quarter last year. Equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on BCRX shares. Bank of America raised their price objective on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, July 1st. Wedbush raised their price target on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an “outperform” rating in a report on Monday, June 30th. Royal Bank Of Canada restated an “outperform” rating and set a $13.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, June 30th. Wall Street Zen upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 26th. Finally, Needham & Company LLC restated a “buy” rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a research note on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $16.70.

Insider Buying and Selling at BioCryst Pharmaceuticals

In other news, Director Theresa Heggie sold 70,000 shares of the stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the transaction, the director directly owned 65,352 shares in the company, valued at approximately $556,145.52. This represents a 51.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.10% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.